DAX19.043 +0,2%ESt504.726 -0,1%MSCIW3.740 +0,2%Dow43.575 +0,4%Nas18.884 -0,4%Bitcoin91.670 +2,6%Euro1,0535 -0,1%Öl73,82 +1,0%Gold2.669 +0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 MicroStrategy 722713 Bayer BAY001 Tesla A1CX3T Rheinmetall 703000 Porsche PAG911 Volkswagen (VW) vz. 766403 Coinbase A2QP7J Mercedes-Benz Group (ex Daimler) 710000 Palantir A2QA4J Amazon 906866 Siemens Energy ENER6Y Deutsche Telekom 555750 NEL ASA A0B733 EVOTEC 566480
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Anleger unentschlossen: DAX stabil -- Wall Street fällt ins Minus-- NVIDIA übertrifft Erwartungen -- Bitcoin: Neuer Rekord -- Mercedes: Sparkurs -- MicroStrategy, Medios, Rheinmetall im Fokus
Top News
NVIDIA-Aktie von Ausblick belastet: NVIDIA mit kräftigen Zuwächsen bei Gewinn und Umsatz - Starke Prognose nicht stark genug NVIDIA-Aktie von Ausblick belastet: NVIDIA mit kräftigen Zuwächsen bei Gewinn und Umsatz - Starke Prognose nicht stark genug
NASDAQ 100-Handel aktuell: NASDAQ 100 zum Handelsstart leichter NASDAQ 100-Handel aktuell: NASDAQ 100 zum Handelsstart leichter
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Gilead Sciences Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
84,06 EUR -0,41 EUR -0,49 %
XETRA
88,47 USD -0,15 USD -0,17 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.103,79 Mrd. EUR

KGV17,99Div. Rendite3,70%

WKN885823

ISINUS3755581036

SymbolGILD

Gilead Sciences Aktien News

DatumMeistgelesen
ReutersGilead trades that made millions on COVID-19 drug news raise eyebrows
ReutersGilead study shows shorter 5-day course of remdesivir works as well as 10-day one
ReutersGilead study shows shorter 5-day course of remdesivir works as well as 10-day one
ReutersHigher dose of Gilead-Galapagos drug meets ulcerative colitis study goals
ReutersUPDATE 2-Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals
ReutersUPDATE 1-Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals
ReutersGilead-Galapagos's drug meets main goals of ulcerative colitis study
ReutersGilead to end coronavirus drug trials, adding to access worry -researchers
ReutersUPDATE 3-Gilead ties up with generic drugmakers for COVID-19 drug supply
ReutersExclusive: Iran-linked hackers recently targeted coronavirus drugmaker Gilead - sources
ReutersExclusive: Iran-linked hackers recently targeted coronavirus drugmaker Gilead - sources
ReutersUPDATE 1-U.S. Doctors want details on federal distribution of Gilead coronavirus drug
ReutersDoctors want details on federal distribution of Gilead coronavirus drug
ReutersUPDATE 2-Japan approves Gilead Sciences' remdesivir as COVID-19 drug
ReutersUPDATE 1-Japan approves Gilead Sciences' remdesivir as COVID-19 drug
ReutersJapan approves Gilead Sciences' remdesivir as COVID-19 drug
ReutersJapan approves Gilead Sciences' remdesivir as COVID-19 drug
ReutersWill Gilead price its coronavirus drug for public good or company profit?
ReutersWill Gilead price its coronavirus drug for public good or company profit?
ReutersGilead in talks to expand global supply of COVID-19 drug remdesivir
ReutersUPDATE 1-Gilead in talks to expand global supply of COVID-19 drug remdesivir
ReutersGilead in talks to expand global supply of COVID-19 drug remdesivir
ReutersMaker of coronavirus trial drug aims for wide distribution - Gilead CEO
ReutersUPDATE 2-Maker of coronavirus trial drug aims for wide distribution -Gilead CEO
ReutersCoronavirus trial drug remdesivir's maker aims for wide distribution - Gilead CEO
ReutersUPDATE 1-Coronavirus trial drug remdesivir's maker aims for wide distribution -Gilead CEO
ReutersUPDATE 3-Gilead to work with partners to ramp up production of potential coronavirus treatment
ReutersGilead to work with partners to ramp up production of potential coronavirus treatment
ReutersUPDATE 2-Gilead to work with partners to ramp up production of potential coronavirus treatment
ReutersGilead aims to expand remdesivir output for COVID-19, posts flat 1st-quarter results
ReutersUPDATE 1-Gilead aims to expand remdesivir output for COVID-19, posts flat 1st-qtr results
ReutersGilead aims to expand remdesivir output for COVID-19, posts flat first-quarter results
ReutersGilead aims to expand remdesivir output for COVID-19, posts flat 1st-qtr results
ReutersREFILE-Fauci says leak concerns fueled his White House revelation of Gilead drug results
ReutersFauci says leak concerns fueled his White House revelation of Gilead drug results
ReutersFauci says leak concerns fueled his White House revelation of Gilead drug results
ReutersUPDATE 7-Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'
ReutersUPDATE 6-Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'
ReutersUPDATE 5-Data on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'
ReutersData on Gilead drug raises hopes in pandemic fight, Fauci calls it 'highly significant'

Gilead Sciences News

Gilead Sciences News: auf dieser Seite finden Sie alle Gilead Sciences News und Nachrichten zur Gilead Sciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Gilead Sciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Gilead Sciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.